Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

JW, a Juno-WuXi AppTec China JV, Raises $90 Million for CAR-T Drugs

publication date: Mar 8, 2018

JW Therapeutics of Shanghai closed an impressive $90 million Series A financing with the goal of bringing best-in-class immunotherapies to China. JW is a joint venture formed by Seattle's Juno Therapeutics, an important cell therapy biotech, and WuXi AppTec, the China CRO/CMO. The JV will combine Juno's CAR-T therapies with WuXi's China development and manufacturing expertise. Along with the financing, JW reported the CFDA has accepted its IND submission for JWCAR029, a CD19 CAR-T therapy that will be tested in B-cell malignancies. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital